Merck & Company (MRK) Shares are Down -0.34%

On a relative basis, the stock has outperformed the S&P 500 by 0.33% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The 4-week change in the price of the stock is -1.7% and the stock has fallen -0.34% in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.29% and the 50-Day Moving Average is 2.45%.The 200 Day SMA reached 13.94% Merck & Co., Inc. is up 12.25% in the last 3-month period. Year-to-Date the stock performance stands at 20.79%.


Merck & Company (MRK) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $56. The average forecast of all the analysts is $65.92 and the expected standard deviation is $7.65.

Company shares have received an average consensus rating of Hold for the current week Merck & Company (NYSE:MRK): stock was range-bound between the intraday low of $62.06 and the intraday high of $62.62 after having opened at $62.45 on Fridays session. The stock finally closed in the red at $62.45, a loss of -0.16%. The stock remained in the red for the whole trading day. The total traded volume was 12,432,293 shares. The stock failed to cross $62.62 in Fridays trading. The stocks closing price on Thursday was $62.38.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.